|Dompé Farmaceutici SpA, of Milan, Italy||Reparixin||Inhibits interleukin-8||COVID-19||Brazil’s regulatory agency, Anvisa, cleared a phase II/III trial in severe COVID-19 patients|
|Mesoblast Ltd., of Melbourne, Australia||Remestemcel-L||Mesenchymal stem cell-based therapy||COVID-19||Received ethics approval to include Australian hospitals in phase III study in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome|
|Mustang Bio Inc., of Worcester, Mass.||MB-107||Lentiviral gene therapy||X-linked severe combined immunodeficiency||FDA granted orphan designation|
|Oblato Inc., of Oklahoma City, a subsidiary of Gtreebnt Co. Ltd.||OKN-007||Sulfatase inhibitor||Diffuse intrinsic pontine glioma||FDA granted rare pediatric disease designation|
|Oblato Inc., of Oklahoma City, a subsidiary of Gtreebnt Co. Ltd.||OKN-007||Sulfatase inhibitor||Malignant glioma||FDA granted orphan designation|
|Pharmacyte Biotech Inc., of Laguna Hills, Calif.||Cypcaps||Genetically engineered human cells encapsulated using the Cell-in-a-Box technology||Pancreatic cancer||Submitted IND to FDA for a phase IIb trial in patients with locally advanced, inoperable disease|
For more information about individual companies and/or products, see Cortellis.